Jesus M. Banales, Mercedes Iñarrairaegui, Ander Arbelaiz, Piotr Milkiewicz, Jordi Muntané, Luis Muñoz‐Bellvis, Adelaida La Casta, Luis M. Gonzalez, Enara Arretxe, Cristina Alonso, Ibon Martínez‐Arranz, Ainhoa Lapitz, Alvaro Santos‐Laso, Matias A. Avila, Maria L. Martínez‐Chantar, Luis Bujanda, Jose J.G. Marin, Bruno Sangro, Rocio I.R. Macias – 16 October 2018 – Early and differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) by noninvasive methods represents a current clinical challenge.

Meritxell Ventura‐Cots, Ariel E. Watts, Monica Cruz‐Lemini, Neil D. Shah, Nambi Ndugga, Peter McCann, A. S. Barritt, Anant Jain, Samhita Ravi, Carlos Fernandez‐Carrillo, Juan G. Abraldes, Jose Altamirano, Ramon Bataller – 16 October 2018 – Risk of alcoholic cirrhosis is determined by genetic and environmental factors. We aimed to investigate if climate has a causal effect on alcohol consumption and its weight on alcoholic cirrhosis. We collected extensive data from 193 sovereign countries as well as 50 states and 3,144 counties in the United States.

Jesus M. Banales, Mercedes Iñarrairaegui, Ander Arbelaiz, Piotr Milkiewicz, Jordi Muntané, Luis Muñoz‐Bellvis, Adelaida La Casta, Luis M. Gonzalez, Enara Arretxe, Cristina Alonso, Ibon Martínez‐Arranz, Ainhoa Lapitz, Alvaro Santos‐Laso, Matias A. Avila, Maria L. Martínez‐Chantar, Luis Bujanda, Jose J.G. Marin, Bruno Sangro, Rocio I.R. Macias – 16 October 2018 – Early and differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) by noninvasive methods represents a current clinical challenge.

Young‐Sun Lee, Myung Han Hyun, Sun Young Yim, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun – 16 October 2018

Fien A. von Meijenfeldt, Ton Lisman – 16 October 2018

Juan G. Abraldes, Jonel Trebicka, Naga Chalasani, Gennaro D’Amico, Don C. Rockey, Vijay H. Shah, Jaime Bosch, Guadalupe Garcia‐Tsao – 15 October 2018 – Portal hypertension (PH) is the main driver of cirrhosis decompensation, the main determinant of death in patients with cirrhosis. PH results initially from increased intrahepatic vascular resistance. Subsequently, increased inflow from splanchnic vasodilation and increased cardiac output lead to a further increase in portal pressure (PP). Reducing PP in cirrhosis results in better outcomes. Removing the cause of cirrhosis might improve PP.

Philip Rosenthal, Simon C. Ling, Steven H. Belle, Karen F. Murray, Norberto Rodriguez‐Baez, Sarah J. Schwarzenberg, Jeffrey Teckman, Hsing‐Hua S. Lin, Kathleen B. Schwarz, for the Hepatitis B Research Network (HBRN) – 15 October 2018 – The optimal management strategy for children with immune‐tolerant chronic hepatitis B virus (HBV) infection remains unknown. The purpose of this clinical trial was to determine the safety and efficacy of therapy with entecavir and peginterferon in a group of children in the immune‐tolerant phase of HBV infection.

Arvin Iracheta‐Vellve, Charles D. Calenda, Jan Petrasek, Aditya Ambade, Karen Kodys, Luciano Adorini, Gyongyi Szabo – 15 October 2018 – Bile acids (BAs) activate various dedicated receptors, including the farnesoid X receptor (FXR) and the Takeda G protein‐coupled receptor 5 (TGR5). The FXR agonist obeticholic acid (OCA) is licensed for the treatment of primary biliary cholangitis and has shown promising results in NASH patients, whereas TGR5 agonists target inflammation and metabolism.

Philip Rosenthal, Simon C. Ling, Steven H. Belle, Karen F. Murray, Norberto Rodriguez‐Baez, Sarah J. Schwarzenberg, Jeffrey Teckman, Hsing‐Hua S. Lin, Kathleen B. Schwarz, for the Hepatitis B Research Network (HBRN) – 15 October 2018 – The optimal management strategy for children with immune‐tolerant chronic hepatitis B virus (HBV) infection remains unknown. The purpose of this clinical trial was to determine the safety and efficacy of therapy with entecavir and peginterferon in a group of children in the immune‐tolerant phase of HBV infection.

Ashwin Rammohan, Mettu S. Reddy, Gomathy Narasimhan, Rajesh Rajalingam, Ilankumaran Kaliamoorthy, Naresh Shanmugam, Mohamed Rela – 13 October 2018 – Auxiliary partial orthotopic liver transplantation (APOLT) in selected noncirrhotic metabolic liver diseases (NCMLDs) is a viable alternative to orthotopic liver transplantation (OLT) as it supplements the function of the native liver with the missing functional protein. APOLT for NCMLD is not universally accepted due to concerns of increased technical complications and longterm graft atrophy.